TcL Pharma appoints board member and operations director

French biotech develops antibodies to treat auto-immune diseases

TcL Pharma, a French biotech company dedicated to the development of antibodies for the treatment of auto-immune diseases has appointed Didier Hoch to its board of directors and Jean-Hugues Masgnaux as operations director.

Hoch has 25 years’ experience in the pharmaceutical industry and in vaccines. Between 2000 and 2010 he ran Sanofi Pasteur MSD, where he led the launch of Gardasil. Prior to this, he carried out various management functions at Rhône Poulenc Rorer (1985-2000), then joined Aventis (Europe, Middle-East/African regions) from 2000 to 2010. He is also a past president (2003-2009) of the European Vaccines Manufacturers Association EVM, and since 2006 has presided over the French Pharmaceutical Companies Association LEEM.

Masgnaux began his career as a consultant at Innothera Laboratories & CNI, going on to become manager of Licences & Agreements at Servier Group and product manager for Fournier Group. Between 1996 and 2000 he progressed from senior product manager to regional sales director and then marketing manager at Bayer Pharma. Between 2000 and 2005 he was Infectiology marketing manager for the France subsidiary of the Gruenenthal group, then international project manager and marketing director. In 2005 he took on the role of president of Madaus Laboratories France, becoming president of the Rottapharm/Madaus Group. In July 2009, he set up M&M Conseil and among other activities works as a health expert for Capgemini Consulting.

You may also like

Pharmaceutical

ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research

ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine
Pharmaceutical

Asahi Kasei expands Sonanos portfolio with next-generation excipients for injectable drug formulation

Asahi Kasei has introduced two new speciality grades in its Sonanos excipient line designed to enhance sustained release and solubility in injectable drugs and plans GMP-compliant production by 2027
Ingredients

Roquette launches KLEPTOSE Crysmeb methyl-beta-cyclodextrin for oral and parenteral formulations

The addition of the novel pharmaceutical excipient boosts the company's already extensive cyclodextrins portfolio
Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Decoding your personal health ecosystem: the power of microbiome diagnostics and nutraceuticals

People often talk about a “gut instinct” or a “gut feeling.” Until recently, though, actually discussing digestive health might have seemed unusual, suggests Christina Casén, Senior Vice President, Clinical and Medical Affairs at Genetic Analysis AS
Finance

Nanologica secures first insulin purification order in China

The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Subscribe now